Table 1.
Characteristic | Insurance Typeb | P Valuec | |
---|---|---|---|
Commercial (n = 1 376 308) | Medicaid (n = 286 769) | ||
Age, y | |||
18–34 | 505 628 (36.7) | 167 847 (58.5) | |
35–49 | 433 689 (31.5) | 70 173 (24.5) | <.001 |
50–64 | 436 991 (31.8) | 48 749 (17.0) | |
Female sex | 702 165 (51.0) | 180 363 (62.9) | <.001 |
Rural residence | 389 964 (28.3) | 120 232 (41.9) | <.001 |
Charlson comorbidity index, mean (SD) | 0.29 (0.89) | 0.56 (1.32) | <.001 |
Charlson comorbiditiesd | |||
Myocardial infarction | 5597 (0.4) | 2482 (0.9) | <.001 |
Congestive heart failure | 7539 (0.6) | 4760 (1.7) | <.001 |
Peripheral vascular disease | 8032 (0.6) | 3756 (1.1) | <.001 |
Cerebrovascular disease | 12 586 (0.9) | 5634 (2.0) | <.001 |
Dementia | 210 (0) | 228 (0.1) | <.001 |
Chronic pulmonary disease | 11 467 (0.8) | 3301 (1.1) | <.001 |
Rheumatic disease | 3779 (0.3) | 2006 (0.7) | <.001 |
Peptic ulcer disease | 24 317 (1.8) | 14 242 (5.0) | <.001 |
Mild liver disease | 69 201 (5.0) | 22 394 (7.8) | <.001 |
Diabetes mellitus | |||
Without chronic complications | 104 807 (7.6) | 47 400 (16.5) | <.001 |
With chronic complications | 15 857 (1.2) | 6515 (2.3) | <.001 |
Hemiplegia or paraplegia | 2586 (0.2) | 2955 (1.0) | <.001 |
Renal disease | 11 455 (0.8) | 4247 (1.5) | <.001 |
Any malignant tumore | 31 820 (2.3) | 6621 (2.3) | .92 |
Moderate or severe liver disease | 1251 (0.1) | 1553 (0.5) | <.001 |
Metastatic solid tumor | 4989 (0.4) | 1652 (0.6) | <.001 |
The study sample includes nonpregnant, nondual eligible adults aged 18 to 64 years.
Data are presented as number (percentage) of patients unless otherwise indicated.
P values for differences between insurance types were calculated using χ2 tests for categorical variables and t tests for numeric variables.
Health conditions are Charlson comorbidity index conditions, created using the enhanced International Classification of Diseases, Ninth Revision (ICD-9) algorithm for administrative data. Variables indicate whether conditions were present at any time during 2012 or 2013.
Including lymphoma and leukemia and excluding malignant neoplasm of skin.